The chemical class known as Sp3 inhibitors pertains to a distinct group of compounds that exert their effects by modulating a specific biological process within cells. These inhibitors target molecules involved in cellular signaling pathways, thereby regulating cellular responses and functions. The term Sp3 refers to a specific target protein or molecular entity present within cells. The inhibitors interact with Sp3 or closely related molecules, affecting their activity and subsequently leading to downstream effects on cellular behavior. These inhibitors typically function by binding to Sp3 or its associated molecules, altering their conformation or impeding their interactions with other cellular components. This binding can disrupt signaling cascades that regulate processes such as gene expression, cellular differentiation, and proliferation. By modulating these pathways, Sp3 inhibitors can induce changes in cellular behavior and function. The specificity of Sp3 inhibitors lies in their ability to selectively interact with Sp3 or its associated molecules, avoiding unintended effects on unrelated cellular processes.
Researchers are keenly interested in the development and exploration of Sp3 inhibitors due to their potential implications for understanding fundamental cellular mechanisms. Studying the effects of these inhibitors provides insights into the complex interplay of molecular pathways within cells. Furthermore, the design and synthesis of specific Sp3 inhibitors can offer researchers powerful tools to dissect and manipulate cellular processes, facilitating the elucidation of previously unrecognized molecular interactions. By shedding light on the intricacies of cellular signaling and molecular responses, Sp3 inhibitors contribute to the advancement of basic scientific knowledge in the realm of cellular biology and molecular pharmacology.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits tyrosine kinase activity by binding to the ATP-binding site, preventing phosphorylation and downstream signaling in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases involved in tumor growth and angiogenesis. Blocks the Raf/MEK/ERK pathway and VEGFR, PDGFR, c-Kit receptors. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, interfering with signaling pathways in cancer cells. Used for EGFR-driven cancers. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits EGFR tyrosine kinase activity, hindering cell proliferation and angiogenesis. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2 tyrosine kinases, preventing their autophosphorylation and downstream signaling in breast cancer therapy. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Targets mutant BRAFV600E kinase, inhibiting the MAPK/ERK pathway and impeding tumor growth in melanomas with this mutation. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Similar to Palbociclib, it also inhibits CDK4/6, preventing cell cycle progression and potentially aiding in breast cancer research. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Another CDK4/6 inhibitor used to block cell cycle progression in hormone receptor-positive breast cancer and some other malignancies. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Targets ALK (anaplastic lymphoma kinase) and inhibits its activity in ALK-positive non-small cell lung cancer. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Selectively inhibits EGFR with T790M resistance mutation, preventing downstream signaling in non-small cell lung cancer. | ||||||